Nuveen Real Estate, one of the largest investment managers in the world with $149 billion of assets under management, has agreed to provide a €35m senior secured loan to Breakthrough Properties, a joint venture of Tishman Speyer and Bellco Capital, to finance the acquisition and construction of One Helix, a state-of-the-art life science asset in Amsterdam.
The asset is 100% pre-let to Neogene, a global, clinical-stage biotechnology company pioneering the discovery, development and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers, and a wholly-owned subsidiary of AstraZeneca. Once complete, it will provide a 5,155 sqm, five-storey, office and laboratory building in the south-east of Amsterdam within the medical cluster surrounding the Amsterdam University Medical Center (Amsterdam UMC). The location has been designated as a key life science development area by the municipality of Amsterdam and is the fastest growing life science cluster in the Netherlands. It benefits from an established life science base with an additional 100,000+ sqm of land available for high quality life science developments that will establish the park as the dominant life science hub in Amsterdam.
You can now read the full whitepaper at the link below
